Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Arixtra Should Promote Awareness of VTE: GSK
June 18, 2007
- Mr Sawai Responds to Criticisms
June 18, 2007
- JPA Concerned about Excess of Pharmacists
June 18, 2007
- GENERIC NEWS IN BRIEF
June 18, 2007
- WG Inaugurated to Predict Demand & Supply for Pharmacists
June 18, 2007
- 28 Drugs (13 APIs) Included in NHI Price List
June 18, 2007
- Sales of 23 TSE Section 1 Companies Up 2.2%
June 18, 2007
- 77 Applications for New Drugs Approved in FY2006: PMDA
June 18, 2007
- Reconsider Insurance Coverage of Long-listed Original Drugs, OTC Drug-Like Ethical Drugs: Council
June 18, 2007
- REGULATORY NEWS IN BRIEF
June 18, 2007
- R&D NEWS IN BRIEF
June 18, 2007
- Takeda Looks for Alliance, Acquisition Opportunities: President Hasegawa
June 18, 2007
- Five Medical Devices Recommended for Priority Review
June 18, 2007
- SURVEY／Metabolic Syndrome Affects 19 Mil. Japanese
June 18, 2007
- MEDICAL DEVICE NEWS IN BRIEF
June 18, 2007
- Chuikyo Starts Discussing FY2008 Drug Pricing Reform
June 11, 2007
- Combined Sales, Profits of 4 Major Generic Firms Show Double-Digit Increases
June 11, 2007
- Taiyo Yakuhin: Sales Up but Ordinary Profits Down due to Aggressive Investment
June 11, 2007
- Towa: Operating Profits Up 84% as a Result of "Reasonable Pricing Policy"
June 11, 2007
- Suzuken Launches Given Imaging's Capsule Endoscope
June 11, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…